77: Practical Approaches to Modern Dry Eye Treatment and Management

Episode Description Dry eye disease (DED) is very common among adults; however, it is often undiagnosed and untreated. As DED can have a considerable impact on a patient’s quality of life, early diagnosis and treatment are essential. In this podcast, experts Marc R. Bloomenstein, OD, FAAO; Cory J. Lappin, OD, MS, FAAO; and Selina R. McGee, OD, FAAO, discuss the roles of ophthalmologists and optometrists in managing DED in an evolving treatment landscape, from screening and diagnosis to disease management.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Bausch + Lomb.Marc R. Bloomenstein, OD, FAAO​Schwartz Laser Eye Center​Scottsdale, AZ​Disclosure: Consultant: AbbVie; Allergan Aesthetics; Astellas Pharma US; Azura Ophthalmics; Bausch + Lomb; Bruder Healthcare; Dompé US; LENZ Therapeutics; Ocuphire Pharma, Inc; OCuSOFT Inc; Olleyes; Reichert Technologies; Sight Sciences, Inc; STAAR Surgical Company; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Théa Pharma; Topcon Healthcare; Viatris Inc; Visus Therapeutics, Inc. Speaker’s bureau: AbbVie; Allergan Aesthetics; Bausch + Lomb; Dompé US; Sight Sciences, Inc; STAAR Surgical Company; Viatris Inc.Cory J. Lappin, OD, MS, FAAO​Founder​The Dry Eye Center of Ohio​Cincinnati, OH​Disclosure: Consultant: Alcon; Barti Software; CSI Dry Eye Software; Eyenovia; Lumenis Be, Inc; MYZE; Nordic Pharma, Inc; NORWOOD Device & Diagnostics; NuLids; PRN Vision Group; Rinsada; SCOPE Health Inc; Tarsus Pharmaceuticals; Viatris Inc; Vital Tears. Speaker’s bureau: Bausch + Lomb; Bruder Healthcare; Dompé US; Lumenis Be, Inc; M&S Technologies; Other: Barti Software (Investment); MYZE (Medical Advisory Board Member/Investment); NuLids (Investment).Selina R. McGee, OD, FAAO​Visionary Founder/Owner​BeSpoke Vision​Adjunct Faculty NSUOCO​Past-President Intrepid Eye Society​Secretary/Treasurer Oklahoma Board of Examiners​Edmond, OK​ Disclosure: Consultant: AbbVie; Aldeyra Therapeutics, Inc; Alcon; Amgen, Inc; Avellino Lab USA, Inc; Bausch + Lomb; Bruder Healthcare; Carl Zeiss Meditec; Cynosure and Hahn; Dompé US; KALA BIO, Inc; Lumenis Be, Inc; Optovue; RVL Pharmaceuticals, Inc; ScienceBased Health; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Théa Pharma; Topcon Healthcare; Versant; Viatris Inc Health. Speaker’s bureau: AbbVie; Alcon; Bausch + Lomb; Cynosure and Hahn; Dompé US; Lumenis Be, Inc; Optovue; ScienceBased Health; Sun Pharmaceutical Industries; Tarsus Pharmaceuticals, Inc; Viatris Inc.Faculty, Staff, and Planners’ DisclosuresIn accordance with ACCME Guidelines, PER® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies. This podcast was developed by PER® editorial staff based on an online activity developed with these faculty. To learn more about this topic, including information on the diagnosis, testing, and management of patients with dry eye disease, go to https://www.gotoper.com/courses/archived-webcast-interventional-dry-eye-a-stepwise-treatment-and-management-approach Release DateJune 30, 2025Expiration DateJune 30, 2026 Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.